
Invitation to commentary regarding Nanexa's press release on 21 December 2022

Nanexa AB (publ) comments, on the 22 of December 2022, on the occasion of the press release on 21 December 2022, and invites to a live commentary.

A live commentary in Swedish with Chairman Göran Ando, CEO David Westberg and Director of Business Development Otto Skolling will be held on 22 December at 10:00 am via Infront Direct Studios and viewers will be given the opportunity to ask questions via chat.

[The commentary will be available here.](#)

The comment will also be posted on Nanexas website afterwards.

For additional information, please contact:

David Westberg – CEO, Nanexa AB (publ)

Phone: +46 70 942 83 03

Email: david.westberg@nanexa.se

www.nanexa.com

Erik Penser Bank is the company's Certified Adviser and can be reached on +46 8 463 83 00, email: certifiedadviser@penser.se

About Nanexa AB (publ)

Nanexa is a pharmaceutical company developing injectable drug products based on the proprietary and innovative drug delivery system PharmaShell® – the high drug load delivery system enabling the next generation long-acting injectables through atomic layer precision. Nanexa develops its own products and also has collaboration agreements with several pharma companies, among others AstraZeneca.

Nanexa's share is listed on Nasdaq First North Growth Market in Stockholm (NANEXA).

Attachments

[Invitation to commentary regarding Nanexa's press release on 21 December 2022](#)